Release Date: December 22, 2025

Expiration Date: December 22, 2026

Activity Overview

The characterization of the RAS oncogenes and mutations that lead to their activation has been one of the seminal discoveries in oncology. However, actively exploiting these proteins as a therapeutic strategy in solid-tumor oncology has been made possible only recently with the incorporation of highly specific inhibitors. More recently, novel RAS-directed strategies have been developed, with the potential to address a much wider range of RAS alterations.

This engaging, fast-paced, and interactive Hot Seat program, held in conjunction with the 43rd Annual Chemotherapy Foundation Symposium (CFS^®): Innovative Cancer Therapy for Tomorrow™, brings together expert faculty in the management of lung, gastrointestinal, and gynecological malignancies to discuss the current landscape of agents targeting RAS family members across solid tumors, as well as novel strategies in development with the potential to impact a much broader range of alterations. The expert faculty will address current clinical challenges and opportunities in the treatment of RAS-mutated solid tumors.

This educational activity is an archive of the live virtual symposium held on November 14, 2025.

Target Audience

This educational activity is directed toward physicians, pathologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners interested in KRAS-mutated solid tumors.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Assess the role of KRAS/RAS mutations across solid tumors and biomarker testing implications
Differentiate efficacy and safety profiles of current and emerging KRAS/RAS-targeted therapies in solid tumors
Apply clinical trial data on KRAS/RAS-targeted therapies to individualized treatment selection for patients with solid tumors
Develop appropriate adverse-event mitigation and management approaches for patients with solid tumors receiving KRAS/RAS-targeted therapies

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Revolution Medicines.

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

GET STARTED WITH THIS PROGRAM:

Related Content